AKZO NOBEL SETTLES REMAINING REMERON COURT CASE

Akzo Nobel, the international pharmaceuticals, coatings and chemicals company, confirmed today that it and its US human healthcare business, Organon USA, have settled the remaining claims in an antitrust litigation involving its Remeron® anti-depressant in the United States. This settlement -- with a proposed class of drug wholesalers who purchased Remeron directly from Organon -- amounts to USD 75 million. It resolves the final claims in a series of lawsuits alleging that the Company's conduct involving a patent for the use of Remeron in combination with so-called SSRIs delayed the market introduction of mirtazapine (the generic version of Remeron) and violated the antitrust laws.

Euronext (http://www.euronext.com/news/companypressrelease/0,4616,1700631_11894_640715101,00.html)